Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
Molecular Partners AG - American Depositary Shares (MOLN)
Company Research
Source: GlobeNewswire
New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties’ emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med’s expertise in the development of 212Pb-based TAT and vast proprietary supply of 212Pb and Molecular Partners’ unique Radio-DARPins as an ideal vector for radiopharmaceuticalsMost advanced 212Pb-Radio-DARPin, DLL3-targeted MP0712, starts clinical trials in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the development of targeted alpha-particle therapies (TAT) with 212Pb (l
Show less
Read more
Impact Snapshot
Event Time:
MOLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOLN alerts
High impacting Molecular Partners AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOLN
News
- Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics [Yahoo! Finance]Yahoo! Finance
- Molecular Partners Forms Scientific Advisory Board to Accelerate Development of Targeted RadiotherapeuticsGlobeNewswire
- Molecular Partners (NASDAQ:MOLN) had its price target lowered by analysts at JPMorgan Chase & Co. from $4.00 to $3.75. They now have a "neutral" rating on the stock.MarketBeat
- Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual MeetingGlobeNewswire
MOLN
Analyst Actions
- 12/8/25 - JP Morgan
MOLN
Sec Filings
- 12/8/25 - Form 6-K
- 11/12/25 - Form 6-K
- 10/30/25 - Form 6-K
- MOLN's page on the SEC website